Site icon pharmaceutical daily

Ventricular Assist Devices – World Market Review & Outlook 2019-2025; Anticipating a CAGR of 13.8% – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global
Ventricular Assist Devices Market 2019-2025” report has been
added to ResearchAndMarkets.com’s offering.

The market research report predicts that the global ventricular assist
devices market will grow at a CAGR of 13.8% during the forecast period.

The market has witnessed steady growth in the past few years and
development in technology with the introduction of innovative products
have increased the acceptance of heart assist devices in the market. The
market is fueled by increase in the incidence of heart failure, lack of
heart donors for transplantation, and increasing elderly population.

The market continues to grow and is one of the most widely used devices
for the functioning of heart in cardiac failure and weakened heart
patients. The market is getting revolutionized with the advancement in
technology. Vendors are focusing towards new product launches, product
approvals, and targeting towards end-users perspective. The market
generates the revenue from the key players operating in this field and
some of vendors are Medtronic plc, Reliant Heart Inc., Abbott
Laboratories, Berlin Heart GmbH, Jarvik Heart, Inc., and ABIOMED, Inc.

According to the authors analysis, North America accounted for the
largest share of the global ventricular assist devices market in 2018
and will retain high position during the forecast period. According to
American Heart Association, an estimated 92.1 million population in the
US have at least one type of CVD and by 2030 it is projected that 43.9%
of the US adult population to have some form of CVD.

Favorable reimbursement policies, availability of advanced technologies,
and growing cardiovascular diseases will increase the adoption and
demand of the devices in this region. The Asia Pacific is expected to
grow during the forecast period, owing to factors such as high
prevalence of cardiovascular diseases, increasing healthcare
expenditure, and presence of huge population base.

By Product:

In 2018, the left ventricular assist devices segment occupied the
largest share and is expected to grow at high CAGR during the forecast
period. Increasing number of patients suffering from last-stage heart
failure, advancement in technology such as effectiveness, high survival
rate, and decreased risk of the devices makes the segment the most
common among other VAD devices.

By Design:

In 2018, the implantable ventricular assist devices segment occupied the
largest share and is expected to grow at high CAGR during the forecast
period.

By Application:

By application, the bridge-to-recovery (BTR) therapy generated the
maximum revenue, thus accounting for more than 35% of the global
ventricular assist devices market in 2018 and the segment is expected to
grow at high CAGR during the forecast period. The destination therapy
segment is expected to be the second highest growing segment during the
forecast period.

By Regions:

The market is dominated by North America, followed by Europe and Asia
Pacific. US occupied the major share of the North American market due to
the increasing disease prevalence and availability of advanced
technologies.

Ventricular Assist Devices Market Research Competitive Analysis

The global ventricular assist devices market has massive growth
opportunities in both developed and developing regions. The advancement
and upgradation of devices will increase the competition among vendors.
Many vendors are focusing on product approvals and developing innovative
products to strengthen their product portfolio that intensifies the
market competition.

In October 2018, FDA approved HeartMate 3 left ventricular assist device
developed by Abbott, as a destination therapy for patients with advanced
heart failure. The approval device supported by the Momentum 3 trial
showed a survival rate of 82.8% at two years with rates of suspected
pump thrombosis at only 1.1%. Health Canada issued a Class IV License
with conditions to HeartMate 3 left ventricular assist system developed
by Thoratec Corporation in 2018.

In 2018, Calon Cardio-Technology has launched a clinical trial of the
UK’s first artificial heart pump. In addition, other leading players are
focusing in huge investments on research and development activities to
develop new products to attain maximum share in the market.

Key Vendors:

Key Competitive Facts

The market is highly competitive with all the players competing to gain
market shares. Intense competition, rapid advancements in technology,
frequent changes in government policies, and the prices are key factors
that confront the market.

The requirement of high initial investment, implementation, and
maintenance cost in the market are also limiting the entry of new
players.

Key Takeaways

Topics Covered

1 Industry Outlook

1.1 Industry Overview

1.1.1 Geography

1.1.2 Medical Technologies

1.1.3 Industry Trends

1.2 Total Addressable Market

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition

3.2 Device Benefits

3.3 Segmented Addressable Market (SAM)

3.4 Trends in the Ventricular Assist Devices Market

3.5 Related Markets

3.5.1 Stents

3.5.2 Interventional Cardiology

3.5.3 Angioplasty

4 Market Outlook

4.1 Regulatory Status

4.2 Reimbursement

4.3 Market Segmentation

4.4 PEST Analysis

4.5 Porter Five Forces

5 Market Characteristics

5.1 DRO – Global Ventricular Assist Devices Market Dynamics

5.1.1 Drivers

5.1.1.1 Upsurge in the incidence of cardiovascular disease (CVD)

5.1.1.2 Growing geriatric population

5.1.1.3 Dearth of heart donors across the globe

5.1.2 Opportunities

5.1.2.1 Increased approvals, fun ding, and pipeline products

5.1.2.2 Upsurge in healthcare spending and demand for better treatment
in emerging economies

5.1.3 Restraints

5.1.3.1 High cost of the devices

5.1.3.2 Strict regulatory policies

5.2 DRO – Impact Analysis

5.3 Key Stakeholders

6 Product: Market Size and Analysis

6.1 Overview

6.2 Left Ventricular Assist Devices

6.3 Right Ventricular Assist Devices

6.4 Biventricular Assist Devices

7 Design: Market Size and Analysis

7.1 Overview

7.2 Transcutaneous Ventricular Assist Devices

7.3 Implantable Ventricular Assist Devices

8 Applications: Market Size and Analysis

8.1 Overview

8.2 Bridge-to-Transplant (BTT) Therapy

8.3 Destination Therapy

8.4 Bridge-to-Recovery (BTR) Therapy

8.5 Bridge-to-Candidacy (BTC) Therapy

9 Regions: Market Size and Analysis

9.1 Overview

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 Rest of the World

10 Competitive Landscape

11 Vendor Profiles

11.1 Medtronic PLC

11.1.1 Overview

11.1.2 Business Units

11.1.3 Geographic Presence

11.1.4 Business Focus

11.1.5 SWOT Analysis

11.1.6 Business Strategies

11.2 Abbott Laboratories

11.3 Reliant Heart Inc.

11.4 Jarvik Heart Inc.

11.5 Berlin Heart GmbH

12 Companies to Watch For

12.1 BiVACOR

12.2 ABIOMED, Inc.

12.3 Calon Cardio-Technology Ltd.

12.4 Maquet GmbH (Getinge AB)

12.5 LivaNova PLC

12.6 Evaheart Medical USA, Inc. (Asahi Kasei Corp.)

12.7 Fresenius Medical Care AG & Co. KGaA (XENIOS AG)

For more information about this report visit https://www.researchandmarkets.com/research/92bxkn/ventricular?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Devices

Exit mobile version